首页 › 骨髓增生异常综合征 › 北卡罗来纳州 › Durham
Durham NC 骨髓增生异常综合征临床试验
14项针对 骨髓增生异常综合征的研究正在 Durham及周边约 30 英里内的站点招募参与者。打开研究详情可查看入选标准及联系研究团队的方式。
官方研究文本（英文）
正在为研究招募参与者？将此页面置顶展示 — $99 / 30天 →
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
招募中2 期
- Duke University Medical Center, Durham
- UNC Lineberger Comprehensive Cancer Center, Chapel Hill · 距离 10 英里
Testing the Addition of an IDH2 Inhibitor, Enasidenib, to Usual Treatment (Cedazuridine-Decitabine) for Higher-Risk Myelodysplastic Syndrome (MDS) With IDH2 Mutation (A MyeloMATCH Treatment Trial)
招募中2 期
- Duke University Medical Center, Durham
Phase 1 Study of AUTX-703 in Relapsed/Refractory AML and MDS
招募中1 期
- University of North Carolina at Chapel Hill, Chapel Hill · 距离 10 英里
Ivosidenib (IVO) Monotherapy and Azacitidine (AZA) Monotherapy in Patients With Hypomethylating Agent (HMA) Naive Myelodysplastic Syndromes (MDS) With an IDH1 Mutation
招募中3 期
- Unc Lineberger Comprehensive Cancer Center, Chapel Hill · 距离 10 英里
The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
招募中1/2 期
- Duke University Medical Center, Durham
- UNC Lineberger Comprehensive Cancer Center, Chapel Hill · 距离 10 英里
ICP-248 in Combination With Azacitidine for the Treatment in Patients With Myeloid Malignancies
招募中1 期
- University of North Carolina at Chapel Hill, Chapel Hill · 距离 10 英里
Study of R289 in Patients With Lower-risk Myelodysplastic Syndromes (LR MDS)
招募中1/2 期
- Duke Cancer Institute, Durham
Study of AZD3632 Monotherapy or in Combination With Anticancer Agents in Participants With Advanced Haematologic Malignancies With KMT2Ar, NPM1m, or Other Genotypes Associated With HOX Overexpression
招募中1/2 期
- Research Site, Durham
- Research Site, Chapel Hill · 距离 10 英里
Registry of Older Patients With Cancer
招募中观察性研究
- Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill · 距离 10 英里
A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)
招募中2/3 期
- Duke University, Durham
A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
招募中1/2 期
- Duke University, Durham
- UNC Hospital, Chapel Hill · 距离 10 英里
CLN-049 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)
招募中1 期
- Duke Cancer Center, Durham
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
招募中观察性研究
- Massive Bio SYNERGY-AI site, Chapel Hill · 距离 10 英里
Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic Cancer
招募中观察性研究
- Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill · 距离 10 英里
其他城市的 骨髓增生异常综合征试验
- Houston, TX43 项研究
- Baldwin Park, CA26 项研究
- New York City, NY21 项研究
- Seattle, WA21 项研究
- Washington, DC20 项研究
- Tampa, FL19 项研究
- Boston, MA19 项研究
- Miami, FL17 项研究
- Columbus, OH14 项研究
- St. Louis, MO13 项研究
- Atlanta, GA13 项研究
- Chicago, IL13 项研究
Durham的其他研究
- 乳腺癌64 项研究
- 癌症（所有类型）58 项研究
- 非小细胞肺癌39 项研究
- 多发性骨髓瘤37 项研究
- 急性髓系白血病33 项研究
- 转移性癌症33 项研究
- 前列腺癌32 项研究
- 肺癌32 项研究
- 结直肠癌28 项研究
- 卵巢癌27 项研究
- 慢性淋巴细胞白血病27 项研究
- 心力衰竭26 项研究
数据来自 ClinicalTrials.gov，检索日期：2026年10月6日。每项研究自行设定入选标准，由研究团队决定谁能参与。